Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) on January 10, 2017, filed with the SEC a prospectus (http://nnw.fm/9sGg6) for the sale in the aggregate of $33,842,512 of its common stock. The use of proceeds will be to fund both clinical and non-clinical studies of its product candidates and for general working capital.
Catalyst Pharmaceuticals is a development stage biopharmaceutical company which is developing CPP-115 to treat reduced GABAergic signaling-associated neurological conditions, such as Tourette’s and post-traumatic stress disorder. The FDA has designated CPP-115 orphan drug status in the U.S. for the treatment of infantile spasms. In Europe, for the treatment of West syndrome, it has been granted E.U. orphan medicinal product designation. In addition, the company is also developing…
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.NetworkNewsWire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer